BiotechTube
Remedy Plan Therapeutics

Remedy Plan Therapeutics

San Diego, United States· Est.
remedyplan.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Remedy Plan Therapeutics is pioneering a novel approach to NAMPT inhibition, a core metabolic enzyme implicated in over 20 diseases including cancer, autoimmune disorders, and obesity. Its proprietary drug screening platform has yielded RPT1G, a first-in-class clinical candidate with an unprecedented allosteric mechanism aimed at delivering efficacy without the severe toxicity of prior NAMPT inhibitors. The company is advancing RPT1G in oncology while leveraging its platform to discover new drugs for autoimmune and metabolic indications. With its lead program now in Phase 1, Remedy Plan is positioned to validate a new therapeutic paradigm for a high-value but historically intractable target.

OncologyAutoimmune DisordersMetabolic Disorders

Technology Platform

Proprietary high-throughput phenotypic screening platform designed to discover novel, allosteric (hyperbolic) inhibitors of the NAMPT enzyme, aiming to achieve efficacy without the on-target toxicity that plagued previous competitive inhibitors.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

Validating its hyperbolic NAMPT inhibitor in the clinic could unlock a high-value target for oncology, with blockbuster potential in preventing metastasis.
Success would also create a pipeline-in-a-product opportunity to expand into massive adjacent markets like autoimmune diseases and obesity, where NAMPT dysregulation is also implicated.

Risk Factors

The primary risk is clinical failure due to on-target toxicity or lack of efficacy, as all prior NAMPT inhibitors have failed in development.
The novel mechanism, while promising, is unproven in humans.
As a private, early-stage biotech, the company also faces significant financing and execution risks.

Competitive Landscape

The competitive landscape for safe NAMPT inhibitors is currently open, as no prior candidates have succeeded. However, Remedy Plan competes indirectly with numerous companies developing therapies for cancer metabolism, cancer stem cells, and metastasis through other mechanisms. In autoimmune and metabolic spaces, it would compete with a wide array of established and novel biologic and small molecule therapies.

More companies in Small Molecule Drugs →More companies in United States →